Strain Data Sheet

RBRC00169

Strain Information

Image
BRC No.RBRC00169
TypeTargeted Mutation CongenicCartagena
SpeciesMus musculus
Strain nameB6.Cg-Tnc<tm1Sia>/Rbrc
Former Common nameC57BL/6N-TgH(Tnc), B6-TN, TNKO
H-2 Haplotype
ES Cell lineTT2 [(C57BL/6NCrlj x CBA/JNCrlj)F1]
Background strainC57BL/6NJcl
Appearanceblack [a/a, B/B, C/C]
Strain developmentCongenic strains were developed by Dr. M. Kusakabe, Cell Biology Laboratory, Life Science Tsukuba Research Center, RIKEN since 1992. A lacZ gene and neomycin resistant cassette was transfered into TT2 ES cells to replace the exon 2, just before the translation initiation codon of the Tnc gene. This strain was backcrossed to C57BL/6N.
Strain descriptionTenascin C knock-out mice. This strain is useful for studying the biological function of extracellular matrix tenascin C in vivo, especially in the field of tumor development, tumor metastasis, wound healing, tissue regeneration, angiogenesis, tissue interaction etc. The tenascin C deficient congenic strains were developed by successive backcrossing with A/J (RBRC00007), BALB/cA (RBRC00067), C57BL/6N (RBRC00169), C3H/HeN (RBRC00110) and GRS/A (RBRC00193).
Colony maintenanceHomozygote x HomozygoteHomozygous mutant mice are viable and fertile.
References
Abnormal behavior and neurotransmissions of tenascin gene knockout mouse.
Fukamauchi F, Mataga N, Wang Y J, Sato S, Youshiki A, Kusakabe M
Biochem. Biophys. Res. Commun., 221, 151-156 (1996). 8660327

Effect of tenascin-C deficiency on chemically induced dermatitis in the mouse.
Koyama Y, Kusubata M, Yoshiki A, Hiraiwa N, Ohashi T, Irie S, Kusakabe M
J. Invest. Dermatol., 111, 930-935 (1998). 9856798

Invasion of melanoma in double knockout mice lacking tenascin-X and tenascin-C.
Matsumoto K, Takahashi K, Yoshiki A, Kusakabe M, Ariga H
Jpn. J. Cancer Res., 93, 968-975 (2002). 12359049

Tenascin-C expression and splice variant in habu snake venom-induced glomerulonephritis.
Matsumoto K, Hiraiwa N, Yoshiki A, Ohnishi M, Kusakabe M
Exp. Mol. Pathol., 72, 186-195 (2002). 12009782

Tyrosine hydroxylase activity and its mRNA level in dopaminergic neurons of tenascin gene knockout mouse.
Fukamauchi F, Mataga N, Wang Y J, Sato S, Yoshiki A, Kusakabe M
Biochem. Biophys. Res. Commun., 231, 356-359 (1997). 9070278

Murine tenascin: cDNA cloning, structure and temporal expression of isoforms.
Saga Y, Tsukamoto T, Jing N, Kusakabe M, Sakakura T
Gene, 104, 177-185 (1991). 1717349

PDGF receptor-alpha deficiency in glomerular mesangial cells of tenascin-C knockout mice.
Matsumoto K, Hiraiwa N, Yoshiki A, Ohnishi M, Kusakabe M
Biochem. Biophys. Res. Commun., 290, 1220-1227 (2002). 11811993

Corneal wound healing in tenascin knockout mouse.
Matsuda A, Yoshiki A, Tagawa Y, Matsuda H, Kusakabe M
Invest. Ophthalmol. Visual. Sci., 40, 1071-1080 (1999). 10235540

Can tenascin be redundant in cancer development?
Sakakura T, Kusakabe M
Perspect. Dev. Neurobiol., 2, 111-116 (1994). 7530137

Mice develop normally without tenascin.
Saga Y, Yagi T, Ikawa Y, Sakakura T, Aizawa S
Genes Dev., 6, 1821-1831 (1992). 1383086
more 3 references
Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture.
Nakao N, Hiraiwa N, Yoshiki A, Ike F, Kusakabe M
Am. J. Pathol., 152, 1237-1245 (1998). 9588892

Loss of cortical and thalamic neuronal tenascin-C expression in a transgenic mouse expressing exon 1 of the human Huntington disease gene.
Kusakabe M, Mangiarini L, Laywell E D, Bates G P, Yoshiki A, Hiraiwa N, Inoue J, Steindler D A
J. Comp. Neurol., 430, 485-500 (2001). 11169482

Tenascin knockout mice: barrels, boundary molecules, and glial scars.
Steindler D A, Settles D, Erickson H P, Laywell E D, Yoshiki A, Faissner A, Kusakabe M
J. Neurosci., 15, 1971-1983 (1995). 7534342

Health Report

Examination Date / Room / Rack

Gene

Gene SymbolGene NameChr.Allele SymbolAllele NameCommon NamesPromoterDiseases Related to This Gene
Tnctenascin C4Tnctargeted mutation 1, Shinichi Aizawa
  • autosomal dominant nonsyndromic hearing loss 56(MedGEN)
  • lacZbeta-galactosidase (E. coli)4
  • autosomal dominant nonsyndromic hearing loss 56(MedGEN)
  • neoneomycin resistance gene (E. coli)4mouse phosphoglycerate kinase promoter (PGK promoter)
  • autosomal dominant nonsyndromic hearing loss 56(MedGEN)
  • Phenotype

    Annotation by Mammalian phenotyhpe ontology
  • abnormal CNS synaptic transmission(MP:0002206)

  • abnormal circadian behavior(MP:0020467)

  • abnormal serotonin level(MP:0005322)

  • decreased dopamine level(MP:0005643)

  • hyperactivity(MP:0001399)
  • more 3 phenotypes
  • impaired swimming(MP:0001522)

  • increased stereotypic behavior(MP:0001409)

  • no abnormal phenotype detected(MP:0002169)
  • Detailed phenotype data

    Ordering Information

    Donor DNAE. coli lacZ, mouse phosphoglycerate kinase promoter (PGK promoter), E. coli neo, mouse tenascin genomic DNA
    Research applicationNeurobiology Research
    Specific Term and ConditionsIn publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Am. J. Pathol., 152, 1237-1245 (1998). J. Invest. Dermatol., 111, 930-935 (1998). Invest. Ophthalmol. Visual. Sci., 1071-1080 (1999).
    DepositorRIKEN BRC (RIKEN BRC)
    Strain Statusan icon for Frozen embryosFrozen embryos
    an icon for Frozen spermFrozen sperm
    Strain AvailabilityRecovered litters from cryopreserved embryos (2 to 4 months)
    Cryopreserved sperm (within 1 month)
    Cryopreserved embryos (within 1 month)
    Additional Info.Necessary documents for ordering:
    1. Order form (Japanese / English)
    2. Category I MTA: MTA for distribution with RIKEN BRC (Japanese / English)
    3. Acceptance of responsibility for living modified organism (Japanese / English)

    Genotyping protocol -PCR-

    BRC mice in Publications

    Nakamura-Ishizu A, Okuno Y, Omatsu Y, Okabe K, Morimoto J, Uede T, Nagasawa T, Suda T, Kubota Y.
    Extracellular matrix protein tenascin-C is required in the bone marrow microenvironment primed for hematopoietic regeneration.
    Blood 119(23) 5429-37(2012) 22553313
    Yonemura A, Semba T, Zhang J, Fan Y, Yasuda-Yoshihara N, Wang H, Uchihara T, Yasuda T, Nishimura A, Fu L, Hu X, Wei F, Kitamura F, Akiyama T, Yamashita K, Eto K, Iwagami S, Iwatsuki M, Miyamoto Y, Matsusaki K, Yamasaki J, Nagano O, Saya H, Song S, Tan P, Baba H, Ajani JA, Ishimoto T.
    Mesothelial cells with mesenchymal features enhance peritoneal dissemination by forming a protumorigenic microenvironment.
    Cell Rep 43(1) 113613(2024) 38232734
    Xu M, Ye Z, Zhao X, Guo H, Gong X, Huang R.
    Deficiency of tenascin-C attenuated cardiac injury by inactivating TLR4/NLRP3/caspase-1 pathway after myocardial infarction.
    Cell Signal 86 110084(2021) 34271086
    Imanaka-Yoshida K, Matsumoto K, Hara M, Sakakura T, Yoshida T.
    The dynamic expression of tenascin-C and tenascin-X during early heart development in the mouse.
    Differentiation 71(4-5) 291-8(2003) 12823230
    Tashjian RZ, Zitnay J, Kazmers NH, Veerabhadraiah SR, Zelada AC, Honeggar M, Smith MC, Chalmers PN, Henninger HB, Jurynec MJ.
    Tenascin C deletion impairs tendon healing and functional recovery after rotator cuff repair.
    J Orthop Res (2024) 39601211
    Matsumoto K, Takahashi K, Yoshiki A, Kusakabe M, Ariga H.
    Invasion of melanoma in double knockout mice lacking tenascin-X and tenascin-C.
    Jpn J Cancer Res 93(9) 968-75(2002) 12359049
    Ito K, Morimoto J, Kihara A, Matsui Y, Kurotaki D, Kanayama M, Simmons S, Ishii M, Sheppard D, Takaoka A, Uede T.
    Integrin α9 on lymphatic endothelial cells regulates lymphocyte egress.
    Proc Natl Acad Sci U S A 111(8) 3080-5(2014) 24516133
    Kubo Y, Ishikawa K, Mori K, Kobayashi Y, Nakama T, Arima M, Nakao S, Hisatomi T, Haruta M, Sonoda KH, Yoshida S.
    Periostin and tenascin-C interaction promotes angiogenesis in ischemic proliferative retinopathy.
    Sci Rep 10(1) 9299(2020) 32518264